Pulmonary HypertensionPVRI GoDeepNCT05329714
PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension
An observational study of Pulmonary Hypertension and Global Health, run by University of Giessen at 1 site in Germany.
Trial summary
PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Pulmonary Hypertension, Global Health
- How many people
- 40,000 participants
- Where
- 1 siteGermany
- Study dates
- 30 Jan 2020to 30 Jan 2055
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Global cohort of patients with pulmonary hypertension (PH)
Who may be able to join
- Clinical Diagnosis of Pulmonary Hypertension
Who cannot join
- none
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
University Giessen PH Center
Giessen, Hesse, 35392
Henning Gall, henning.gall@innere.med.uni-giessen.de
About this study
Official title: PVRI Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension
PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center. Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.
Read the detailed description
PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center.
Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.
The data provided by PVRI-GoDeep will support academia to perform scientific projects in the field of PH. Pharmaceutical / commercial companies will be charged fee for access to PVRI-GoDeep data and / or analysis, thereby creating revenues exclusively devoted to support the PVRI mission and the registries entering their data into PVRI-GoDeep. All requests from academia or commercial companies are to be decided by the PVRI-GoDeep consortium, serving as Use and Access Committee.
- Conditions
- Pulmonary Hypertension, Global Health
- Keywords
- Pulmonary Hypertension, Data Integration, Standardization, Global Health, Quality Indicators
- Medical subject headings
- Hypertension, Pulmonary
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with Pulmonary Hypertension | Patients with a diagnosis of pulmonary hypertension typically diagnosed via right heart catheterization. | |
| Control Group | Participating PH centers can optionally provide data about patients with exclusion of pulmonary hypertension |
What is being measured
The primary outcome is the main question the study is designed to answer.
Global analysis of PH patients
Global comparison and analysis of the course of disease of PH patients
Measured: From entry into the registry up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2022
- Study start30 Jan 2020
- Primary completion30 Jan 2050 (estimated)
- Study completion30 Jan 2055 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Pulmonary HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 40,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Giessen
- Sponsor type
- University, hospital or other
- Collaborators
- Imperial College London, Johns Hopkins University, Stanford University, University of Sheffield, University of Pittsburgh, University of Pavia, Hospital de Niños de la Santísima Trinidad, Academy of Medical Sciences of Ukraine, The Methodist Hospital Research Institute, Vanderbilt University Medical Center, Mayo Clinic, National and Kapodistrian University of Athens, Aristotle University Of Thessaloniki, University Hospital of Targu Mures, Romania, University Hospital Heidelberg, Milpark Hospital, University of Minnesota, Royal Prince Alfred Hospital, Sydney, Australia, Fiona Stanley Hospital, Sunshine Coast University Hospital, China-Japan Friendship Hospital, Medical University of Graz, National Hospital Organization Okayama Medical Center, Royal Hobart Hospital, University Hospital, Zürich, Universidad Nacional de La Plata, Gold Coast Hospital and Health Service
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05329714
- Sponsor's protocol ID
- PVRIGoDeep
- Acronym
- PVRI GoDeep
- Status last verified
- Apr 2025
- First submitted
- 14 Mar 2022
- Last updated
- 4 Apr 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Yogeswaran A, Funderich M, Kiely DG, Annis JS, Brittain E, Bogaard HJ, Balasubramanian A, Hassoun PM, Howard L, Lawrie A, Wilkins MR, Thenappan T, Elwing J, Jose A, Lichtblau M, Ulrich S, Harbaum L, Klose H, Sweatt AJ, Zamanian RT, Lau EM, Kuronuma K, Matsubara H, Dwyer N, Sirenko Y, Torbas O, Eichstaedt CA, Grunig E, Lavender M, Arvanitaki A, Giannakoulas G, Frauendorf M, Williams PG, Zhai Z, Zhang Z, Anthi A, Dima E, Sabbour H, Saleh K, Ghio S, Scelsi L, De Luque Figueroa J, Orozco-Levi M, Ramirez-Sarmiento A, Sivakumaran S, Anderson J, Chan SY, King I, Olschewski H, Ghofrani HA, Grimminger F, Majeed RW, Wilhelm J, Tello K, Seeger W; PVRI GoDeep Consortium. Predictive Power of Pulmonary Artery Stiffness-Right Ventricular Interplay, But Not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep Meta-Registry Analysis. Chest. 2026 Aug 26:S0012-3692(26)06476-7. doi: 10.1016/j.chest.2026.07.5243. Online ahead of print.
PubMed 42648467Yogeswaran A, Gall H, Funderich M, Wilkins MR, Howard L, Kiely DG, Lawrie A, Hassoun PM, Sirenklo Y, Torbas O, Sweatt AJ, Zamanian RT, Williams PG, Frauendorf M, Arvanitaki A, Giannakoulas G, Saleh K, Sabbour H, Cajigas HR, Frantz R, Al Ghouleh I, Chan SY, Brittain E, Annis JS, Pepe A, Ghio S, Orfanos S, Anthi A, Majeed RW, Wilhelm J, Ghofrani HA, Richter MJ, Grimminger F, Sahay S, Tello K, Seeger W; Pulmonary Vascular Research Institute GoDeep Consortium. Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension: A Pulmonary Vascular Research Institute GoDeep Meta-Registry Analysis. Chest. 2024 Sep;166(3):585-603. doi: 10.1016/j.chest.2024.03.018. Epub 2024 Mar 19.
PubMed 38508334
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PVRI Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension
- ClinicalTrials.gov ID
- NCT05329714
- Acronym / sponsor ID
- PVRI GoDeep / PVRIGoDeep
- Conditions
- Pulmonary Hypertension, Global Health
- Keywords
- Pulmonary Hypertension, Data Integration, Standardization, Global Health, Quality Indicators
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40,000 participants (estimated)
- Lead sponsor
- University of GiessenUniversity, hospital or other
- Collaborators
- Imperial College London, Johns Hopkins University, Stanford University, University of Sheffield, University of Pittsburgh, University of Pavia, Hospital de Niños de la Santísima Trinidad, Academy of Medical Sciences of Ukraine, The Methodist Hospital Research Institute, Vanderbilt University Medical Center, Mayo Clinic, National and Kapodistrian University of Athens, Aristotle University Of Thessaloniki, University Hospital of Targu Mures, Romania, University Hospital Heidelberg, Milpark Hospital, University of Minnesota, Royal Prince Alfred Hospital, Sydney, Australia, Fiona Stanley Hospital, Sunshine Coast University Hospital, China-Japan Friendship Hospital, Medical University of Graz, National Hospital Organization Okayama Medical Center, Royal Hobart Hospital, University Hospital, Zürich, Universidad Nacional de La Plata, Gold Coast Hospital and Health Service
- Study start
- 30 Jan 2020 (actual)
- Primary completion
- 30 Jan 2050 (estimated)
- Study completion
- 30 Jan 2055 (estimated)
- First posted
- 15 Apr 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center. Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.
Detailed description
PVRI-GoDeep is a PH Meta-Registry, run under the umbrella of the Pulmonary Vascular Research Institute (PVRI). It merges anonymized PH patient related data from various local registries around the world run under the responsibility of PVRI members. It will be operated under the auspices of the University of Giessen/Giessen PH center.
Combining deep phenotyping with worldwide outreach, PVRI-GoDeep aims to offer insights into specific geographical and ethnical profiles of PH, to deepen the epidemiological, clinical and molecular understanding of this disease and to promote strategies for improved individualized treatment of PH patients.
The data provided by PVRI-GoDeep will support academia to perform scientific projects in the field of PH. Pharmaceutical / commercial companies will be charged fee for access to PVRI-GoDeep data and / or analysis, thereby creating revenues exclusively devoted to support the PVRI mission and the registries entering their data into PVRI-GoDeep. All requests from academia or commercial companies are to be decided by the PVRI-GoDeep consortium, serving as Use and Access Committee.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with Pulmonary Hypertension | – | –Patients with a diagnosis of pulmonary hypertension typically diagnosed via right heart catheterization. |
| Control Group | – | –Participating PH centers can optionally provide data about patients with exclusion of pulmonary hypertension |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Global cohort of patients with pulmonary hypertension (PH)
Key inclusion criteria (1 listed)
- Clinical Diagnosis of Pulmonary Hypertension
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Global analysis of PH patients
Time frame: From entry into the registry up to 10 years
Global comparison and analysis of the course of disease of PH patients
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2025.
- Derived from this study: PubMed 42648467Yogeswaran A, Funderich M, Kiely DG, Annis JS, Brittain E, Bogaard HJ, Balasubramanian A, Hassoun PM, Howard L, Lawrie A, Wilkins MR, Thenappan T, Elwing J, Jose A, Lichtblau M, Ulrich S, Harbaum L, Klose H, Sweatt AJ, Zamanian RT, Lau EM, Kuronuma K, Matsubara H, Dwyer N, Sirenko Y, Torbas O, Eichstaedt CA, Grunig E, Lavender M, Arvanitaki A, Giannakoulas G, Frauendorf M, Williams PG, Zhai Z, Zhang Z, Anthi A, Dima E, Sabbour H, Saleh K, Ghio S, Scelsi L, De Luque Figueroa J, Orozco-Levi M, Ramirez-Sarmiento A, Sivakumaran S, Anderson J, Chan SY, King I, Olschewski H, Ghofrani HA, Grimminger F, Majeed RW, Wilhelm J, Tello K, Seeger W; PVRI GoDeep Consortium. Predictive Power of Pulmonary Artery Stiffness-Right Ventricular Interplay, But Not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep Meta-Registry Analysis. Chest. 2026 Aug 26:S0012-3692(26)06476-7. doi: 10.1016/j.chest.2026.07.5243. Online ahead of print.
- Derived from this study: PubMed 38508334Yogeswaran A, Gall H, Funderich M, Wilkins MR, Howard L, Kiely DG, Lawrie A, Hassoun PM, Sirenklo Y, Torbas O, Sweatt AJ, Zamanian RT, Williams PG, Frauendorf M, Arvanitaki A, Giannakoulas G, Saleh K, Sabbour H, Cajigas HR, Frantz R, Al Ghouleh I, Chan SY, Brittain E, Annis JS, Pepe A, Ghio S, Orfanos S, Anthi A, Majeed RW, Wilhelm J, Ghofrani HA, Richter MJ, Grimminger F, Sahay S, Tello K, Seeger W; Pulmonary Vascular Research Institute GoDeep Consortium. Comparison of Contemporary Risk Scores in All Groups of Pulmonary Hypertension: A Pulmonary Vascular Research Institute GoDeep Meta-Registry Analysis. Chest. 2024 Sep;166(3):585-603. doi: 10.1016/j.chest.2024.03.018. Epub 2024 Mar 19.
Related trials for Pulmonary Hypertension
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Active, not recruitingPhase 1
A Pilot Study of Microbiota Transplant With Antibiotic Preconditioning and Fiber Supplementation in Pulmonary Arterial Hypertension (GUT RESTORE-PAH)
Pulmonary Arterial Hypertension
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pulmonary Hypertension and Global Health, run by University of Giessen at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Raphael W Majeed (+49 641 985 42502, raphael.majeed@innere.med.uni-giessen.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Global analysis of PH patients (time frame: From entry into the registry up to 10 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05329714, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2025.